However,with appropriate studies to determine effective dosing regimens, basedon the current studies, it is likely that work to further promotethe investigation of targeting GPR35 in NAFLD and/or NASH would befruitful. This evidence concerns the gene GPR35 and metabolic dysfunction-associated steatotic liver disease.